How to Keep Your CEO Off the Jumbotron
Why do executives, like the Astronomer CEO, keep taking needless risks? Bloomberg Opinion columnist Beth Kowitt knows a lot — maybe too much — about their bad behavior. (Source: Bloomberg)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
Dycom Industries (DY) Surged on a Mix of Growth Drivers
Aristotle Capital Boston, LLC, an investment advisor, released its 'Small Cap Equity Strategy' second quarter 2025 investor letter. A copy of the letter can be downloaded here. The second quarter started with a risk-off environment from the previous quarter, but later regained momentum driven by broad-based elements. In the second quarter, the strategy delivered a return of 3.25% net of fees (3.41% gross of fees) underperforming the 8.50% total return of the Russell 2000 Index. For more information on the fund's best picks in 2025, please check its top five holdings. In its second quarter 2025 investor letter, Aristotle Capital Small Cap Equity Strategy highlighted stocks such as Dycom Industries, Inc. (NYSE:DY). Headquartered in Palm Beach Gardens, Florida, Dycom Industries, Inc. (NYSE:DY) provides contracting services to the telecommunications infrastructure and utility industries. The one-month return of Dycom Industries, Inc. (NYSE:DY) was 6.36%, and its shares gained 45.73% of their value over the last 52 weeks. On July 22, 2025, Dycom Industries, Inc. (NYSE:DY) stock closed at $252.68 per share, with a market capitalization of $7.309 billion. Aristotle Capital Small Cap Equity Strategy stated the following regarding Dycom Industries, Inc. (NYSE:DY) in its second quarter 2025 investor letter: "Dycom Industries, Inc. (NYSE:DY), a provider of engineering and construction services to the telecommunications and cable television industries, benefitted from continued growth in its core business, funding tailwinds, and expanding margins as demand for wireline services continues to grow. We maintain our position as we believe the company remains well positioned for longer-term growth alongside secular trends for expanding fiber deployments to support faster broadband connectivity speeds and opportunities to deploy fiber to rural or underserved areas across the country." A 360 degree view of a partially constructed tower, featuring various pieces of equipment and constructionmaterials. Dycom Industries, Inc. (NYSE:DY) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 36 hedge fund portfolios held Dycom Industries, Inc. (NYSE:DY) at the end of the first quarter, which was 37 in the previous quarter. In the fiscal first quarter of 2026, Dycom Industries, Inc. (NYSE:DY) reported $1.259 billion in revenue, reflecting a 10.2% increase over Q1 2025. While we acknowledge the potential of Dycom Industries, Inc. (NYSE:DY) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. In another article, we covered Dycom Industries, Inc. (NYSE:DY) and shared best Russell 2000 stocks that have garnered recommendations from Wall Street analysts. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
Yahoo
23 minutes ago
- Yahoo
MasterCard price target lowered to $612 from $640 at Truist
Truist lowered the firm's price target on MasterCard (MA) to $612 from $640 and keeps a Buy rating on the shares. Truist likes the setup for the FinTech sector as earnings results in totality should be solid, and the group has underperformed of late, the analyst tells investors in a research note. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on MA: Disclaimer & DisclosureReport an Issue Here's what Wall Street experts are saying about GM and Ford ahead of earnings American Airlines, MasterCard announce extension of partnership Japan Just Found a Way to Earn XRP Without Spending a Yen Starbucks downgraded, Oracle initiated: Wall Street's top analyst calls MasterCard resumed with a Buy at Deutsche Bank Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
23 minutes ago
- Yahoo
Boston Scientific lifts annual profit view on steady heart devices demand
(Reuters) -Boston Scientific raised its annual profit forecast on Wednesday, after strong demand for its heart devices helped the U.S. medical device maker beat second-quarter profit estimates. Shares of the Massachusetts-based company rose 2.3% in premarket trading following the results. A rise in surgical procedures has benefited medical device manufacturers such as Boston Scientific, as it boosted sales and helped offset broader concerns about healthcare spending pressures. Analysts said hospital utilization trends were robust during the second quarter, with hospital checks pointing to high single-digit volume growth - well above the historical average. Boston Scientific's main growth drivers, Farapulse and Watchman, which use short high-voltage pulses to treat certain abnormal heart rhythm conditions, saw strong demand during the quarter. Farapulse, approved in the U.S. to treat certain patients with intermittent atrial fibrillation, competes with Johnson & Johnson's Varipulse and Medtronic's PulseSelect in the market for pulsed field ablation (PFA) systems. "Cardiovascular end-markets remain robust," Truist analyst Richard Newitter said ahead of the earnings, adding that Boston, followed by Medtronic, are in the best position at the moment to benefit from the growing and accelerating PFA market. Rival Johnson & Johnson last week posted strong medtech sales, aided by its heart devices, Varipulse and Trupulse. Boston Scientific expects 2025 adjusted profit of $2.95 to $2.99 per share, up from the prior view of $2.87 to $2.94 earlier. It posted adjusted profit of 75 cents per share for the second quarter, topping analysts' average estimate of 72 cents, according to data compiled by LSEG. The company's cardiovascular unit reported quarterly sales of $3.34 billion, surpassing estimates of $3.20 billion. Revenue came in at $5.06 billion for the quarter, topping estimates of $4.9 billion.
